Biosimilars: Maximizing Adoption
To achieve savings benefits from the coming wave of biosimilars, biosimilars must be adopted by prescribers, members, [...]
Biosimilars: Payer Decision Making
Once the first Humira biosimilar, Amjevita, launched in the United States in January, payers needed to begin [...]
The Financial Impact of Biosimilars
Introduction There is a coming wave of changes arriving soon to the pharmacy market in the form [...]
The Big Event: Humira Biosimilar Launches
Introduction Today is the day! The Big Event of 2023 is the launch of multiple Humira biosimilars [...]
Biosimilars: The Coming Wave
Introduction There is a big wave of changes coming to the pharmacy market. The extent of the [...]
Biosimilars: A Brief Introduction
The coming market introduction of several significant biosimilars is predicted to bring a wave of change to [...]
Pharmacy Provisions of the Inflation Reduction Act
Introduction I read the 725-page draft of the Deficit Reduction Act[1] so you don’t have to. Well, [...]